natgillin/translations-raw huggingface dataset:
Sikkerheden og virkningen af clopidrogrel plus ASA er blevet evalueret i 3 dobbeltblindede studier, der omfattede mere end 61.900 patienter i CURE-, CLARITY- og COMMIT-studierne, hvor clopidogrel plus ASA sammenlignes med ASA alene. 
The safety and efficacy of clopidogrel plus ASA have been evaluated in three double-blind studies involving over 61,900 patients: the CURE, CLARITY and COMMIT studies, comparing clopidogrel plus ASA to ASA alone, both treatments given in combination with other standard therapy.
• fluconazol, voriconazol, ciprofloxacin eller chloramphenicol, lægemidler der anvendes til behandling af svampeinfektioner. 
• fluconazole, voriconazole, ciprofloxacin, or chloramphenicol, medicines to treat bacterial and fungal infections,
• hvis du lider af en alvorlig leversygdom. 
• If you suffer from severe liver disease.
Methotrexatdoser over 20 mg ugentligt bør anvendes med forsigtighed sammen med kombinationen clopidogrel/acetylsalicylsyre, da ASA kan hæmme den renale clearance af methotrexat, hvilket kan føre til knoglemarvstoksicitet. 
Due to the presence of ASA, methotrexate used at doses higher than 20 mg/week should be used with caution with the combination of clopidogrel/acetylsalicylic acid as it can inhibit renal clearance of methotrexate, which may lead to bone marrow toxicity.
• fordøjelsesbesvær eller halsbrand. 
• indigestion or heartburn.
Som dobbelt antitrombotisk middel skal kombinationen clopidogrel/acetylsalicylsyre anvendes med forsigtighed til patienter med øget risiko for blødning pga. traumer, kirurgi eller andre patologiske tilstande samt til patienter, der samtidigt behandles med andre NSAID'er, inklusive Cox-2-hæmmere, heparin, glykoprotein IIb/IIIahæmmere, selektive serotoningenoptagelseshæmmere (SSRI'er) eller trombolytika. 
As a dual antiplatelet agent, the combination of clopidogrel/acetylsalicylic acid should be used with caution in patients who may be at risk of increased bleeding from trauma, surgery or other pathological conditions and in patients receiving treatment with other NSAIDs including Cox-2 inhibitors, heparin, glycoprotein IIb/IIIa inhibitors, selective serotonin reuptake inhibitors (SSRIs), or thrombolytics.
hvis du får smerter i maveregionen eller blødning i mave eller tarme (rød eller sort afføring). 
if you have any stomach or abdominal pain or bleeding in the stomach or bowels (red
Antallet af patienter, som oplevede det primære endepunkt [kardiovaskulær død (CV), myokardieinfarkt (MI) eller apopleksi] var 582 (9,3 %) i clopidogrel plus ASA-gruppen og 719 (11,4 %) i ASA-gruppen, hvilket giver en relativ risikoreduktion på 20 % (95 % CI: 10 %-28 %; p = 0,00009) for clopidogrel plus ASA-gruppen (en relativ risikoreduktion (RRR) på 17 %, når patienterne fik konservativ behandling, 29 %, når de fik ballonudvidelse (perkutan transluminal koronar angioplastik (PTCA)) med eller uden stent, og 10 %, når de fik koronar bypassoperation (CABG). 
The number of patients experiencing the primary endpoint [cardiovascular (CV) death, myocardial infarction (MI), or stroke] was 582 (9.3%) in the clopidogrel plus ASA group and 719 (11.4%) in the ASA group, a 20% relative risk reduction (RRR) (95% CI of 10%-28%; p=0.00009) for the clopidogrel plus ASA group [17% relative risk reduction when patients were treated conservatively, 29% when they underwent percutaneous transluminal coronary angioplasty (PTCA) with or without stent and 10% when they underwent coronary artery bypass graft (CABG)].
Brug ikke lægemidlet efter den udløbsdato, der står på pakningen efter Exp. Udløbsdatoen er den sidste dag i den nævnte måned. 
Do not use this medicine after the expiry date which is stated on the carton, bottle and blister after EXP.
Yderligere oplysninger om Clopidogrel/Acetylsalicylsyre Teva findes på Det Europæiske Lægemiddelagenturs hjemmeside http://www.ema.europa.eu. 
Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu.
Efter første anbrud af tabletbeholderen: Anvendes inden for 30 dage. 
After first opening the bottle use within 30 days.
Acetylsalicylsyre må ikke gives indtil den 24. uge med amenorré (graviditetens 5. måned), medmindre det er absolut nødvendigt. 
Until the 24th amenorrhea week (5th month of pregnancy), acetylsalicylic acid should not be given unless clearly necessary.
Hvis du er bekymret over blødningen, skal du omgående kontakte din læge (se afsnit 4 'Bivirkninger'). 
However, if you are concerned by your bleeding, you should contact your doctor straightaway (see section 4
Clopidogrel/Acetylsalicylsyre Teva udleveres i blisters i pakningsstørrelser på 14, 28 og 30 film-overtrukne tabletter, eller i tabletneholdere i en pakningsstørrelse på 30 filmovertrukne tabletter. 
Clopidogrel/Acetylsalicylic acid Teva is supplied in blisters in pack sizes of 14, 28 and 30 film-coated tablets or in bottles in a pack size of 30 film-coated tablets.
Hvis du er gravid eller ammer, har mistanke om, at du er gravid, eller planlægger at blive gravid, skal du spørge din læge eller apotekspersonalet til råds, før du tager Clopidogrel/Acetylsalicylsyre Teva. 
If you are pregnant or suspect that you are pregnant, you should tell your doctor or your pharmacist before taking Clopidogrel/Acetylsalicylic acid Teva.
• hvis du har aktiv blødning såsom et mavesår eller blødning i hjernen. 
• If you have a medical condition that is currently causing bleeding such as a stomach ulcer or bleeding within the brain.
Farmakokinetikken og den antitrombotiske effekt, målt ved ex vivo trombocytaggregationsstudie, adskiller sig alt efter CYP2C19-genotype. 
Clopidogrel active metabolite pharmacokinetics and antiplatelet effects, as measured by ex vivo platelet aggregation assays, differ according to CYP2C19 genotype.
Acetylsalicylsyre hæmmer trombocytaggregation ved irreversibel hæmning af prostaglandincyklooxygenase og hæmmer derved dannelsen af tromboxan A2, en inducer af trombocytaggregation og vasokonstriktion. 
Acetylsalicylic acid inhibits platelet aggregation by irreversible inhibition of prostaglandin cyclo-oxygenase and thus inhibits the generation of thromboxane A2, an inducer of platelet aggregation and vasoconstriction.
• akut koronarsyndrom uden elevation af ST-segmentet (ustabil angina eller myokardieinfarkt uden forekomst af Q-takker) inklusive patienter, som får indsat stent efter perkutan koronar intervention 
• Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction) including patients undergoing a stent placement following percutaneous
Sjældne bivirkninger (kan påvirke op til 1 ud af 1000 patienter): • svimmelhed (fornemmelse af at snurre rundt). 
Rare side effect (may affect up to 1 in 1000 people): • vertigo.
• acetylsalicylsyre eller andre non-steroide antiinflammatoriske stoffer (NSAID), der sædvanligvis anvendes til behandling af smertefulde og/eller betændelseslignende tilstande i muskler eller led (gigt). 
• ASA or another non-steroidal anti-inflammatory medicine usually used to treat painful and/or inflammatory conditions of muscle or joints,
Hvide HDPE-tabletbeholdere og børnesikrede lukker af grøn polypropylen (PP) med tørremiddel. 
White HDPE bottles and green polypropylene (PP) child-resistant closures with dessicant.
Tabletkernen: lactosemonohydrat, mikrokrystallinsk cellulose, hydroxypropylcellulose 100 cP, crospovidon (type A), stearinsyre, croscarmellosenatrium, hydrogeneret vegetabilsk olie og natriumlaurilsulfat. 
• The other ingredients are: Tablet core: lactose monohydrate, microcrystalline cellulose, hydroxypropylcellulose 100 cP, crospovidone (type A), stearic acid, croscarmellose sodium, hydrogenated vegetable oil and sodium lauril sulfate.
Clopidogrel/Acetylsalicylsyre Teva er et fast-dosis kombinationspræparat til fortsat behandling ved: 
Clopidogrel/Acetylsalicylic acid Teva is a fixed-dose combination medicinal product for continuation of therapy in:
Clopidogrel/Acetylsalicylsyre Teva udleveres i blisters i pakningsstørrelser på 10, 14, 28, 30, 50, 90 og 100 filmovertrukne tabletter, eller i tabletbeholdere i en pakningsstørrelse på 30 filmovertrukne tabletter. 
Clopidogrel/Acetylsalicylic acid Teva is supplied in blisters in pack sizes of 10, 14, 28, 30, 50, 90 and 100 film-coated tablets or in bottles in a pack size of 30 film-coated tablets.
Patienterne blev randomiseret til clopidogrel (300 mg initial støddosis efterfulgt af 75 mg/dag, N = 6.259) plus ASA (75-325 mg en gang daglig) eller ASA alene (N = 6.303), (75-325 mg en gang daglig) i kombination anden standardbehandling. 
Patients were randomised to clopidogrel (300 mg loading dose followed by 75 mg/day, N=6,259) plus ASA (75-325 mg once daily) or ASA alone (N=6,303), (75-325 mg once daily) and other standard therapies.
• hvis du lider af en alvorlig nyresygdom. 
• If you suffer from severe kidney disease.
Plasmasalicylatkoncentrationer over 300 mg/l (1,67 mmol/l) tyder på forgiftning. 
The lethal dose of acetylsalicylic acid is 25-30 g. Plasma salicylate concentrations above 300 mg/l (1.67 mmol/l) suggest intoxication.
Quinolin yellow aluminium lake (E104) Talcum 
Titanium dioxide (E171) Quinoline yellow aluminium lake (E104) Talc
Tabletovertræk: hypromellose, polydextrose, titandioxid (E171), quinolin yellow aluminium lake (E104), talcum, maltodextrin, triglycerider, middelkædelængde og gul jernoxid (E172). 
Tablet coating: hypromellose, polydextrose, titanium dioxide (E171), quinoline yellow aluminium lake (E104), talc, maltodextrin, medium chain triglycerides and iron oxide yellow (E172).
• probenecid, benzbromaron eller sulfipyrazon, lægemidler til behandling af urinsur gigt. 
• probenecid, benzbromarone, or sulfinpyrazone, medicines used to treat gout,
Hvide HDPE-tabletbeholdere i flere lag og børnesikrede lukker af grøn polypropylen (PP) med tørremiddel. 
White HDPE multi-layer bottles and green polypropylene (PP) child-resistant closures with dessicant.
Svagt lyserøde til lyserøde, filmovertrukne tabletter. 
Light pink to pink, film-coated capsule shaped tablets.
Der er dog foretaget et antal retrospektive analyser for at evaluere denne effekt hos patienter i behandling med clopidogrel, for hvem der foreligger resultater af genotyping: CURE (n = 2721), CHARISMA (n = 2428), 
There have been a number of retrospective analyses, however, to evaluate this effect in patients treated with clopidogrel for whom there are genotyping results: CURE (n=2721), CHARISMA (n=2428), CLARITY-TIMI 28 (n=227), TRITON-TIMI 38 (n=1477), and ACTIVE-A (n=601), as well as a number of published cohort studies.
Brug af anden medicin sammen med Clopidogrel/Acetylsalicylsyre Teva Fortæl det altid til lægen eller apotekspersonalet, hvis du tager anden medicin eller har gjort det for nylig. 
Other medicines and Clopidogrel/Acetylsalicylic acid Teva Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription.
Sikkerheden ved samtidig administration af kombinationen clopidogrel/acetylsalicylsyre og andre trombolytika er ikke fastlagt, og der skal derfor udvises forsigtighed (se pkt. 
The safety of the concomitant administration of the combination of clopidogrel/acetylsalicylic acid with other thrombolytic agents has not been formally established and should be undertaken with caution (see section 4.4).
Da kombinationen clopidogrel/acetylsalicylsyre indeholder ASA, er det kontraindiceret i graviditetens tredje trimester. 
Due to the presence of ASA, the combination of clopidogrel/acetylsalicylic acid is contraindicated during the third trimester of pregnancy.
Clopidogrel/Acetylsalicylsyre Teva indeholder lactose. 
Clopidogrel/Acetylsalicylic acid Teva contains lactose.
Som forholdsregel bør amning ophøre under behandling med kombinationen clopidogrel/acetylsalicylsyre. 
Breast-feeding should be discontinued during treatment with the combination of clopidogrel/acetylsalicylic acid.
Du kan finde yderligere oplysninger om Clopidogrel/Acetylsalicylsyre Teva på Det Europæiske Lægemiddelagenturs hjemmeside: http://www.ema.europa.eu. 
This leaflet was last revised in <MM/YYYY> Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu.
Der findes ingen information vedrørende overdosering af kombinationen clopidogrel/acetylsalicylsyre. 
There is no information concerning overdose with the combination of clopidogrel/acetylsalicylic acid.
• muskelsmerter 
• muscular pain
Du skal holde op med at tage andre lægemidler, der indeholder clopidogrel, mens du tager Clopidogrel/Acetylsalicylsyre Teva. 
You should stop other clopidogrel treatment while you are taking Clopidogrel/Acetylsalicylic acid Teva.
14 filmovertrukne tabletter 28 filmovertrukne tabletter 30 filmovertrukne tabletter 
Film-coated tablet 14 film-coated tablets 28 film-coated tablets 30 film-coated tablets
• allergiske hudreaktioner 
• skin allergy
heparin, ATC-kode: B01AC30. 
5.1 Pharmacodynamic properties Pharmacotherapeutic group: platelet aggregation inhibitors excl. Heparin, ATC Code: B01AC30.
Der findes ingen fertilitetsdata for kombinationen clopidogrel/acetylsalicylsyre. 
There are no fertility data with the combination of clopidogrel/acetylsalicylic acid.
Kombinationen clopidogrel/acetylsalicylsyre skal anvendes med forsigtighed til patienter i samtidig behandling med glykoprotein IIb/IIIa-hæmmere (se pkt. 
The combination of clopidogrel/acetylsalicylic acid should be used with caution in patients who receive concomitant glycoprotein IIb/IIIa inhibitors (see section 4.4).
Efter gentagen dosering med clopidogrel 75 mg daglig i 10 dage svarede den ADP-inducerede trombocytaggregation hos patienter med alvorligt nedsat leverfunktion til den, der blev set hos raske studiepersoner. 
After repeated doses of 75 mg clopidogrel per day for 10 days in patients with severe hepatic impairment, inhibition of ADP-induced platelet aggregation was similar to that observed in healthy subjects.
• svimmelhed • prikkende fornemmelse og følelsesløshed. 
• sensation of tingling and numbness.
Anden samtidig behandling med ASA 
Other concomitant therapy with ASA
Systemorganklasse Almindelig Ikke almindelig Sjælden Meget sjælden, ikke kendt nedsat nyrefunktion, kardial dekompensation, nefrotisk syndrom eller samtidig behandling med diuretika)* glomerulonefrit, forhøjet blodkreatinin 
Acute renal impairment (especially in patients with existing renal impairment, heart decompensation, nephritic syndrome, or concomitant treatment with diuretics)*, glomerulonephritis, blood creatinine increased
Som forholdsregel frarådes samtidig anvendelse af stærke eller moderate CYP2C19-hæmmere (se pkt. 
As a precaution concomitant use of strong or moderate CYP2C19 inhibitors should be discouraged (see sections 4.4 and 5.2).
Tag ikke Clopidogrel/Acetylsalicylsyre Teva 
Do not take Clopidogrel/Acetylsalicylic acid Teva
Samtidig administration af kombinationen clopidogrel/acetylsalicylsyre og orale antikoagulantia kan ikke anbefales, da det kan øge blødningsintensiteten (se pkt. 
The concomitant administration of the combination of clopidogrel/acetylsalicylic acid with oral anticoagulants is not recommended since it may increase the intensity of bleeding (see section 4.5).
Gastrointestinale (GI) bivirkninger, der omfatter mavesmerter, halsbrand, kvalme, opkastning og gastrointestinal blødning, kan forekomme. 
GI undesirable effects including stomach pain, heartburn, nausea, vomiting, and GI bleeding may occur.
MÆRKNING, DER SKAL ANFØRES PÅ DEN YDRE EMBALLAGE 
PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING BOTTLE LABEL
Hjælpestof, som behandleren skal være opmærksom på: Hver filmovertrukket tablet indeholder 117,8 mg lactose (som lactosemonohydrat) 
Each film-coated tablet contains 117.8 mg of lactose (as lactose monohydrate).
Øvre gastrointestinale lidelser (øsofagitis, øsofageal ulceration, perforation, erosiv gastritis, erosiv duodenitis, gastroduodenal ulcus/perforationer)*, 
Gastrointestinal and retroperitoneal haemorrhage with fatal outcome, pancreatitis, gastro-duodenal ulcer/perforations*,
4.4), aplastisk anæmi, pancytopeni, agranulocytose, alvorlig trombocytopeni, granulocytopeni, anæmi, erhvervet hæmofili A. 
Thrombotic thrombocytopenic purpura (TTP) (see section 4.4), aplastic anaemia, pancytopenia, agranulocytosis, severe thrombocytopenia, granulocytopenia, anaemia, acquired haemophilia A.
• hvis du er allergisk over for clopidogrel, acetylsalicylsyre eller et af de øvrige indholdsstoffer i 
• If you are allergic to clopidogrel, acetylsalicylic acid (ASA) or any of the other ingredients of this medicine (listed in section 6).
I overensstemmelse med resultaterne ovenfor, blev det vist i en metaanalyse af 6 studier med 335 clopidogrelbehandlede ved steady-state, at eksponeringen for den aktive metabolit nedsattes med 28 % for personer med moderat metabolisme, og 72 % for personer med ringe metabolisme. 
Consistent with the above results, in a meta analysis including 6 studies of 335 clopidogrel-treated subjects at steady state, it was shown that active metabolite exposure was decreased by 28% for intermediate metabolisers, and 72% for poor metabolisers while platelet aggregation inhibition (5 μM ADP) was decreased with differences in IPA of 5.9% and 21.4%, respectively, when compared to extensive metabolisers.
Hjælpestof, som behandleren skal være opmærksom på: Hver filmovertrukket tablet indeholder 102,06 mg lactose (som lactosemonohydrat) 
Each film-coated tablet contains 102.6 mg of lactose (as lactose monohydrate).
Clopidogrel/Acetylsalicylsyre Teva bør gives som en enkelt daglig dosis på 75 mg/75 mg. 
Clopidogrel/Acetylsalicylic acid Teva should be given as a single daily 75 mg/75 mg dose.
Almindelige bivirkninger (kan påvirke op til 1 ud af 10 patienter): 
Common side effects (may affect up to 1 in 10 people):
Samtidig administration af kombinationen clopidogrel/acetylsalicylsyre og orale antikoagulantia kan ikke anbefales, da det kan øge blødningstendensen (se pkt. 
The concomitant administration of the combination of clopidogrel/acetylsalicylic acid with oral anticoagulants is not recommended since it may increase the intensity of bleeding (see section 4.4).
Clopidogrel/Acetylsalicylsyre Teva bør gives som en enkelt daglig dosis på 75 mg/100 mg. 
Clopidogrel/Acetylsalicylic acid Teva should be given as a single daily 75 mg/100 mg dose.
Anafylaktisk shock*, serumsygdom, anafylaktoide reaktioner, forværring af symptomer på fødeallergi*, krydsallergiske lægemiddelreaktioner mellem thienopyridiner (såsom ticlopidin, prasugrel), (se pkt. 
Anaphylactic shock*, serum sickness, anaphylactoid reactions, aggravation of allergic symptoms of food allergy*, cross-reactive drug hypersensitivity
Det er usandsynligt, at Clopidogrel/Acetylsalicylsyre Teva vil påvirke din evne til at føre motorkøretøj eller betjene maskiner. 
Driving and using machines Clopidogrel/Acetylsalicylic acid Teva should not affect your ability to drive or to use machines.
Efter gentagen dosering med clopidogrel 75 mg daglig var hæmningen af ADP-induceret trombocytaggregation lavere (25 %) hos studiepersoner med alvorlig nyresygdom (kreatininclearance 5-15 ml/min) end den, der blev set hos raske studiepersoner. 
After repeated doses of 75 mg clopidogrel per day in subjects with severe renal disease (creatinine clearance from 5 to 15 ml/min), inhibition of ADP-induced platelet aggregation was lower (25%) than that observed in healthy subjects, however, the prolongation of bleeding time was similar to that seen in healthy subjects receiving 75 mg of clopidogrel per day.
Hvis du ønsker yderligere oplysninger om Clopidogrel/Acetylsalicylsyre Teva, skal du henvende dig til den lokale repræsentant for indehaveren af markedsføringstilladelsen: 
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
Det skal du vide, før du begynder at tage Clopidogrel/Acetylsalicylsyre Teva 
What you need to know before you take Clopidogrel/Acetylsalicylic acid Teva
Selvom mindre GI-symptomer såsom dyspepsi er almindelige og kan forekomme på alle tidspunkter i behandlingen. 
Although minor upper GI symptoms, such as dyspepsia, are common and can occur anytime during therapy, physicians should remain alert for signs of ulceration and bleeding, even in the absence of previous GI symptoms.
* Rapporteret i publiceret information for ASA (frekvens ”ikke kendt”(. 
Bleeding time prolonged, neutrophil count decreased, platelet count decreased * Information reported in published information for ASA (frequency “not known”).
• nyresygdom 
• kidney disease
Dyrestudier har påvist reproduktionstoksicitet efter administration af en prostaglandinsyntesehæmmer (se pkt. 
In animals, administration of a prostaglandin synthesis inhibitor has been shown to result in reproductive toxicity (see section 5.3).
Tabletovertræk: hypromellose, polydextrose, titandioxide (E171), talcum, maltodextrin, triglycerider, middelkædelængde, gul jernoxid (E172), carmin (E120), rød jernoxid (E172). 
Tablet coating: hypromellose, polydextrose, titanium dioxide (E171), talc, maltodextrin, medium chain triglycerides, iron oxide yellow (E172).
• skal du fortælle lægen, at du er i behandling med Clopidogrel/Acetylsalicylsyre Teva: hvis du skal have foretaget en planlagt operation (også hos tandlægen). 
• You should tell your doctor if a surgery (including dental) is planned.
Kombinationen clopidogrel/acetylsalicylsyre må ikke anvendes til patienter med stærkt nedsat leverfunktion (se pkt. 
The combination of clopidogrel/acetylsalicylic acid must not be used in patients with severe renal impairment (see section 4.3).
Triglycerider, middelkædelængde Jernoxid, gul (E 172) Carmin (E120) 
Medium chain triglycerides Iron oxide yellow (E172) Carmine (E120) Iron oxide red (E172)
Clopidogrel/Acetylsalicylsyre Teva 75 mg/100 mg 
Clopidogrel/Acetylsalicylic acid Teva 75 mg/100 mg
Clopidogrel/Acetylsalicylsyre Teva 75 mg/75 mg 
Clopidogrel/Acetylsalicylic acid Teva 75 mg/75 mg
• brændende fornemmelse i maven og/eller spiserøret 
• burning in stomach and/or oesophagus
Øre og labyrint 
Eye disorders Ear and labyrinth disorders
Mave-tarm-kanalen Gastrointestinal 
Gastrointestinal disorders
• omeprazol, esomeprazol eller cimetidin til behandling af for meget mavesyre. 
• omeprazole, esomeprazole or cimetidine, medicines to treat upset stomach,
Hypoglykæmi*, urinsur 
Hypoglycaemia*, gout* (see section
Der er ingen data fra anvendelse af kombinationen clopidogrel/acetylsalicylsyre til gravide kvinder. 
No clinical data on exposure to the combination of clopidogrel/acetylsalicylic acid during pregnancy are available.
Triglycerider, middelkædelængde Jernoxid, gul (E 172) 
Medium chain triglycerides Iron oxide yellow (E172)
Mens du er i behandling med Clopidogrel/Acetylsalicylsyre Teva: 
While you are taking Clopidogrel/Acetylsalicylic acid Teva:
• forstoppelse 
• ulcer perforation
• Svært nedsat nyrefunktion. 
• Severe hepatic impairment.
Croscarmellosenatrium Hydrogeneret vegetabilsk olie. 
Croscarmellose sodium Hydrogenated vegetable oil Sodium lauril sulfate
Kontakt lægen, før du tager denne medicin, hvis lægen har fortalt dig, at du ikke tåler visse sukkerarter (f.eks. lactose). 
Clopidogrel/Acetylsalicylic acid Teva contains lactose If you have been told by your doctor that you have an intolerance to some sugars (e.g. lactose), contact your doctor before taking this medicine.
• udsætte fostret for: - Kardiopulmonal toksicitet (med præmatur lukning af ductus arteriosus og pulmonalhypertension); - Renal dysfunktion, der kan udvikle sig til nyresvigt med oligo-hydroamniose. 
- cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary
• ticlopidin, der er et andet lægemiddel mod dannelse af blodpropper. 
• ticlopidine, other antiplatelet agent.
Clopidogrel/Acetylsalicylsyre Teva 75 mg/75 mg filmovertrukne tabletter er gule, filmovertrukne, kapselformede tabletter. 
What Clopidogrel/Acetylsalicylic acid Teva looks like and contents of the pack Clopidogrel/Acetylsalicylic acid Teva 75 mg/75 mg film-coated tablets are yellow, film-coated capsule shaped tablets.
YDERKARTON til blisters 
PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CARTON for blisters